Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
In a trading channel. Just needs volume to reverse it and break that ceiling. Love to see it before 15th May or it could be the update that triggers it. Patience is always tested when multiple attempts fail prior to the volume that is needed to produce the momentum to breach previous peak.
Given the fervor for 'all things American' and the fact that Kainos has a big footprint and significant revenue stream in the USA I'm surprised this hasn't soared already. Similar businesses over the water command a far higher p/e than here despite the constant comment that it's on the high side (for here!). Next week's update should reassure and set it firmly back on the ascent.
Entry into ICU market expands revenue potential.
The size and scope of Ondines Steriwave continues to grow given its undeniable reduction in environment acquired infections and their huge cost to Healthcare globally. It really is the gold standard as roll out continues to attract new users and surgeon chat confirms statistics.
I think the approval of Steriwave, after recent trials, into the NHS has now primed Ondine for takeover by a big provider with the size to scale it. Ondine has 7 applications for Steriwave in its sights and pending Ph3 approval into the USA market.
Hospital acquired infections cost the NHS a fortune.
SSIs are one of the most common healthcare-associated infections (HAIs) and affect one in every 20 patients who undergo a surgical procedure in the NHS. SSIs can cost up to £100,000 per patient, and the overall cost of HAIs to NHS England is over £2 billion a year.
There's a fine line between dismissing a share at this level and FOMO as appraisal and adoption snowballs. It really screams the perfect juncture for a player like J&J to take this on and scale it exponentially. The proof of effectiveness is out there and rapidly gaining surgeon comment.
Carol Cross CEO has take this from concept, thorough R&D and proving, trialled and accepted by surgeons and now on the cusp of large commercial rollout. At 62yrs of age and with her background and stature I am sure that she sees the best exit strategy is to sell to a big player who can scale up. The huge degree of success in reducing the need for antibiotics in post operative hospital care is evident and becoming globally 'viral' as surgeons and care teams communicate the savings. Steriwave is simple, quick, non-invasive and safe as it does not compromise the nasal biome weeks after the operation. A 75% reduction in the use of antibiotics to treat post op hospital acquired infections seems to be universal when Steriwave is used. That saves hospitals millions of pounds and thousands of days post op intervention and bed-blocking. It's a total no-brainer and just needs a major [probably US] Healthcare company to make her an offer and immediately scale it globally. As she holds 50% or so of the shares it would be a done deal. I mentioned 20p but I personally see it worth a lot more. Hopefully Carol Cross thinks likewise. I really cannot see any other direction than north from here.
Given the raft of positive news now coming out from surgeons in all quarters of the profession, oropharyngeal, orthopaedics etc I have written to the company to request that they give possible financial projections of uptake. The recent NHS news must have huge potential and it would be great to see some meat on the bones.
Carolyn Cross is 62, has steered Steriwave from concept, through R&D to commercialisation. It's now on the cusp of exponential adoption looking at success rates. Now is the time to put her exit strategy in play as she holds just under 50% of the shares in Ondine. Time to put it into play and watch the multiples scale it. The fact that a phase 3 trial in the USA is happening probably dictates where that bid will come from given the massive stateside potential. Just a matter of time and patience whilst this frustratingly low shareprice plays out.